Cerevance's novel KCNK13 inhibitor CVN293 demonstrated favorable tolerability and robust brain penetration in a Phase 1 trial with 72 healthy volunteers, supporting its potential as a disease-modifying treatment for neuroinflammation-driven neurodegenerative diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.